Up-regulation of p-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line

Journal of Neuroscience Research

Volumn 87, Issue 4, 2009, Pages 1023-1036

  Zastre, Jason A ^a   Chan, Gary N Y ^a   Ronaldson, Patrick T ^a   Ramaswamy, Manisha ^a   Couraud, Pierre O ^a,b,c   Romero, Ignacio A ^d   Weksler, Babette ^e   Bendayan, Moise ^f   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUT COCHIN   (France)

^c INSERM   (France)

^d OPEN UNIVERSITY   (United Kingdom)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Blood brain barrier; Drug efflux transporters; HIV AIDS; Nuclear receptors; Protease inhibitors

Indexed keywords

ATAZANAVIR; CELL NUCLEUS RECEPTOR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GOLD; MULTIDRUG RESISTANCE PROTEIN 1; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; VALSPODAR; VERLUKAST; BISPHOSPHONIC ACID DERIVATIVE; CYCLOSPORIN DERIVATIVE; OLIGOPEPTIDE; PROPIONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SR 12813; TRITIUM;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG UPTAKE; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LONG TERM EXPOSURE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; VASCULARIZATION;

BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; CYCLOSPORINS; DIPHOSPHONATES; ENDOTHELIUM, VASCULAR; HIV PROTEASE INHIBITORS; HUMANS; MICROVESSELS; OLIGOPEPTIDES; P-GLYCOPROTEIN; PROPIONATES; PYRIDINES; QUINOLINES; RIFAMPIN; RITONAVIR; TRITIUM; UP-REGULATION;

EID: 63849164131     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21898     Document Type: Article

References (61)

1. Akanuma S, Hori S, Ohtsuki S, Fujiyoshi M, Terasaki T. 2008. Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood-brain barrier. Neurochem Int 52:669-674.
2. Aronica E, Gorter JA, Redeker S, Van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, Van Der Valk P, Leenstra S, Baayen JC, Spliet WGM, Troost D. 2005. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46:849-857.
3. Bachmeier CJ, Trickler WJ, Miller DW. 2004. Drug efflux transport properties of 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) and its fluorescent free acid, BCECF. J Pharm Sci 93:932-942.
4. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. 2005. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 22:1259-1268.
5. Bauer B, Hartz AMS, Fricker G, Miller DS. 2004. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66:413-419.
6. Bauer B, Yang X, Hartz AMS, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS. 2006. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70:1212-1219.
7. Beaulieu E, Demeule M, Ghitescu L, Béliveau R. 1997. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326:539-544.
8. Bendayan M. 1995. Colloidal gold post-embedding immunocytochemistry. Progr Histochem Cytochem 29:1-159.
9. Bendayan R, Lee G, Bendayan M. 2002. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57:365-380.
10. Bendayan R, Ronaldson PT, Gingras D, Bendayan M. 2006. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 54:1159-1167.
11. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, Back D. 2003. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 33:551-556.
12. Choo EF, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
13. Dallas S, Zhu X, Baruchel S, Schlichter L, Bendayan R. 2003. Functional expression of the multidrug resistance protein 1 in microglia. J Pharmacol Exper Ther 307:282-290.
14. De Maat MMR, Corine Ekhart G, Huitema ADR, Koks CHW, Mulder JW, Beijnen JH. 2003. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 42:223-282.
15. Denizot F, Lang R. 1986. Rapid colorimetric assay for cell growth and survival - modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89:271-277.
16. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. 2001. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276:33309-33312.
17. Francis GA, Fayard E, Picard F, Auwerx J. 2003. Nuclear receptors and the control of metabolism. Annu Rev Physiol 65:261-311.
18. Geick A, Eichelbaum M, Burk O. 2001. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
19. Gisolf EH, Van Heeswijk RPG, Hoetelmans RWM, Danner SA. 2000. Decreased exposure to saquinavir in HIV-1-infected patients after longterm antiretroviral therapy including ritonavir and saquinavir. AIDS 14:801-805.
20. Goldsmith DR, Perry CM. 2003. Atazanavir. Drugs 63:1679-1693.
21. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, Von Richter O, Zundler J, Kroemer HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
22. Gupta A, Zhang Y, Unadkat JD, Mao Q. 2004. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exper Ther 310:334-341.
23. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CCJ, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296:827-843.
24. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back O, Mulcahy F, Feely J. 2002. St John's Wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53:75-82.
25. Hsu A, Granneman GR, Bertz RJ. 1998. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291.
26. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW. 2001. Induction of P-glycoprotein and cytochrome P450 3a by HIV protease inhibitors. Drug Metab Dispos 29:754-760.
27. Ito K, Olsen SL, Qiu W, Deeley RG, Cole SPC. 2001. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J Biol Chem 276:15616-15624.
28. Kageyama M, Namiki H, Fukushima H, Terasaka S, Togawa T, Tanaka A, Ito Y, Shibata N, Takada K. 2005. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharmaceut Bull 28:130-137.
29. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
30. Kramer-Hämmerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. 2005. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 111:194-213.
31. Lampidis TJ, Castello C, Del Giglio A, Pressman BC, Viallet P, Trevorrow KW, Valet GK, Tapiero H, Savaraj N. 1989. Relevance of the chemical charge of rhodamine dyes to multiple drug resistance. Biochem Pharmacol 38:4267-4271.
32. Langford D, Marquie-Beck J, de Almeida S, Lazzaretto D, Letendre S, Grant I, McCutchan AJ, Masliah E, Ellis RJ. 2006. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 12:100-107.
33. Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
34. Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman J, Gottesman MM, Clarke R. 1996. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br J Cancer 73:154-161.
35. Lombardo L, Pellitteri R, Balazy M, Cardile V. 2008. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res 5:82-92.
36. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R. 2005. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity [1]. J Acquir Immune Defic Syndr 39:635-637.
37. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, Hiramatsu Y. 2005. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol 19:1170-1180.
38. McArthur JC, Brew BJ, Nath A. 2005. Neurological complications of HIV infection. Lancet Neurol 4:543-555.
39. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, Moore JT. 2002. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 16:977-986.
40. Nath A, Sacktor N. 2006. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 19:358-361.
41. Okochi E, Iwahashi T, Tsuruo T. 1997. Monoclonal antibodies specific for P-glycoprotein. Leukemia 11:1119-1123.
42. Owen A, Goldring C, Morgan P, Park BK, Pirmohamed M. 2006. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol 62:237-242.
43. Park S, Sinko PJ. 2005. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exper Ther 312:1249-1256.
44. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. 2000. Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58:361-372.
45. Perloff MD, Von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ. 2000. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 14:1287-1289.
46. Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ. 2001. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 90:1829-1837.
47. Perloff MD, Von Moltke LL, Greenblatt DJ. 2004. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica 34:133-150.
48. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, Von Moltke LL. 2005. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33:764-770.
49. Perloff MD, VonMoltke LL, Fahey JM, Greenblatt DJ. 2007. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 59:947-953.
50. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud P, Roux F. 1998. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71:705-715.
51. Ronaldson PT, Lee G, Dallas S, Bendayan R. 2004. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm Res 21:811-818.
52. Sacktor N. 2002. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 8(Suppl 2):115-121.
53. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. 2004. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 78:10133-10148.
54. Stanley L, Horsburgh B, Ross J, Scheer N, Roland Wolf C. 2006. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 38:515-597.
55. Staudinger JL, Madan A, Carol KM, Parkinson A. 2003. Regulation of drug transporter gene expression by nuclear receptors. Drug Metab Dispos 31:523-527.
56. Störmer E, Von Moltke LL, Perloff MD, Greenblatt DJ. 2002. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 19:1038-1045.
57. Synold TW, Dussault I, Forman BM. 2001. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590.
58. Urquhart BL, Tirona RG, Kim RB. 2007. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566-578.
59. Van der Sandt ICJ, Vos CMP, Nabulsi L, Blom-Roosemalen MCM, Voorwinden HH, De Boer AG, Breimer DD. 2001. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15:483-491.
60. Weksler BB, Subileau EA, Perrie're N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. 2005. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872-1874.
61. Zong J, Pollack GM. 2003. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exper Ther 306:556-562.